MARKET

LIFE

LIFE

aTyr Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.90
-0.02
-0.34%
Closed 16:00 01/24 EST
OPEN
5.81
PREV CLOSE
5.92
HIGH
5.99
LOW
5.80
VOLUME
41.16K
TURNOVER
--
52 WEEK HIGH
10.08
52 WEEK LOW
2.760
MARKET CAP
22.95M
P/E (TTM)
-0.6760
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of LIFE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

LIFE News

  • aTyre Pharma S-1 Shows Registration For $17.25M Common Stock Offering
  • Benzinga.01/17 13:09
  • Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data
  • Zacks.01/08 15:07
  • Company News For Jan 7, 2020
  • Zacks.01/07 14:26
  • aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma
  • Zacks.01/07 14:19

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About LIFE

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
More

Webull offers aTyr Pharma Inc (LIFE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.